the health care provider and patient on a case-by-case basis. In clinical trials, severe psoriasis has been defined as a Psoriasis Area and Severity Index (PASI) score ( 25 3 5 In patients with active PsA despite treatment with TNFi biologic monotherapy, switching to a different TNFi biologic monotherapy is recommended over switching to IL-12/23i biologic, an IL-17i biologic, abatacept, or tofacitinib monotherapy or adding MTX to the current TNFi biologic (Table 3 5 In patients with active PsA